22.3 Septic Arthritis & Acute Microcrystalline Crises

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

22.3 Septic Arthritis & Acute Microcrystalline Crises

Key Takeaways Explain This Topic AI

Septic arthritis is a true orthopedic emergency requiring mandatory diagnostic arthrocentesis prior to the initiation of empiric intravenous antimicrobials; synovial fluid leukocyte count >50,000/µL (frequently >100,000/µL) with ≥75-90% polymorphonuclear neutrophils strongly confirms joint sepsis.

Staphylococcus aureus (including MRSA) is the single most common pathogen across all age groups; sexually active young adults require empiric coverage for Neisseria gonorrhoeae, which presents either as purulent monoarthritis or the classic triad of migratory polyarthralgias, tenosynovitis, and painless vesiculopustular skin lesions.

Empiric intravenous therapy for acute bacterial arthritis consists of IV Vancomycin (15-20 mg/kg q8-12h) plus IV Ceftriaxone (1-2 g daily), combined with immediate orthopedic consultation for emergency joint decompression via urgent arthroscopic lavage, open arthrotomy, or daily closed needle aspiration.

Polarized light microscopy definitively distinguishes crystal arthropathies: monosodium urate (MSU) crystals in gout are needle-shaped and strongly negatively birefringent (bright yellow when parallel to the compensator axis), whereas calcium pyrophosphate dihydrate (CPPD) crystals in pseudogout are rhomboid-shaped and weakly positively birefringent (blue when parallel to the compensator axis).

During an acute gout flare, urate-lowering therapy (e.g., allopurinol, febuxostat) must never be newly initiated or titrated because acute shifts in serum urate prolong the attack; however, ongoing chronic allopurinol must be continued without interruption, and the acute flare should be treated with NSAIDs, low-dose colchicine, or systemic/intra-articular corticosteroids.

Last updated: September 2026

Acute Septic Arthritis: Pathogenesis & Microbiology

Septic (bacterial) arthritis is a medical and orthopedic emergency carrying a 10% to 15% in-hospital mortality rate and permanent joint dysfunction in up to 50% of survivors. Rapid recognition is paramount: bacterial proliferation within a closed synovial space induces rapid, irreversible destruction of articular hyaline cartilage within 24 to 48 hours .

Pathophysiology of Joint Destruction

Absence of Synovial Basement Membrane : The synovial membrane is highly vascularized but lacks a protective limiting basement membrane. Consequently, circulating bacteria readily extravasate across synovial capillaries into the joint space during transient or sustained bacteremia.

The Inflammatory Destruction Cascade :

Bacteria proliferate within synovial fluid, releasing endotoxins, peptidoglycans, and bacterial proteases.

Synovial macrophages and infiltrating neutrophils release massive surges of proinflammatory cytokines ( TNF-alpha, IL-1beta, IL-6, and IL-8 ).

Recruited polymorphonuclear neutrophils (PMNs) release destructive lysosomal enzymes and matrix metalloproteinases (MMPs) that directly digest collagen fibers and proteoglycans within the articular cartilage matrix.

Massive intra-articular purulent exudate accumulates, dramatically elevating intra-articular hydrostatic pressure. High pressure exceeds subchondral capillary perfusion pressure, inducing capillary tamponade, microvascular subchondral bone ischemia, and aseptic avascular necrosis.

Route of Infection

Hematogenous Seeding (Single Most Common Route, >90% of cases) : Secondary to occult bacteremia from skin/soft-tissue infections, intravenous drug use, dental procedures, urinary tract infections, or central venous catheters.

Direct Penetrating Inoculation : Accidental puncture wounds, animal or human bites, arthrocentesis, intra-articular steroid injections, or arthroscopic surgery.

Contiguous Spread : Direct extension from adjacent osteomyelitis (particularly in infants where transphyseal vessels connect the metaphysis to the epiphysis), septic bursitis, or deep periarticular soft-tissue abscesses.

Microbiology of Septic Arthritis

Pathogen Class Causative Microorganism Clinical Context & High-Risk Populations

Gram-Positive Cocci (>75% of non-gonococcal) Staphylococcus aureus (MSSA and MRSA) Leading cause overall in adults and children of all ages . High rates of MRSA in hospitalized patients, nursing home residents, and injection drug users.

Streptococci (~15-20%) Streptococcus pyogenes (GAS), S. pneumoniae , Group B Strep Common in older adults, patients with underlying rheumatoid arthritis, diabetes, or autoimmune disease.

Sexually Transmitted Pathogen Neisseria gonorrhoeae Leading cause of bacterial arthritis in healthy, sexually active adolescents and young adults . Presents as Disseminated Gonococcal Infection (DGI) or purulent monoarthritis.

Gram-Negative Bacilli (~10-15%) Pseudomonas aeruginosa , Escherichia coli , Klebsiella Intravenous drug users (predilection for axial joints: sternoclavicular, sacroiliac, pubic symphysis), elderly, immunosuppressed, urinary tract sepsis.

Pediatric Pathogens Kingella kingae (ages 6 mo to 4 yr); S. aureus Young children; indolent presentation, often culture-negative on standard agar (requires inoculation into blood culture bottles).

Sickle Cell Disease Salmonella species ; S. aureus Predilection for osteomyelitis and septic arthritis due to functional hyposplenism and gastrointestinal micro-infarctions.

The Dual Syndromes of Disseminated Gonococcal Infection (DGI)

Neisseria gonorrhoeae manifests in two distinct clinical presentations:

The Classic Triad of DGI (Bacteremic Form) :

Migratory Polyarthralgias : Asymmetric joint pain migrating across wrists, elbows, knees, and ankles;

Tenosynovitis : Simultaneous inflammation of multiple tendon sheaths, characteristically involving the dorsum of the wrists, fingers, and Achilles tendon;

Dermatitis : Painless, sparse (typically 2 to 10 lesions) vesiculopustular, petechial, or hemorrhagic necrotic pustules on an erythematous base located on the distal extremities.

Diagnostic Rule : Synovial fluid cultures in this bacteremic form are frequently negative (<25% sensitivity) . Diagnosis requires Nucleic Acid Amplification Testing (NAAT) from mucosal sites: urogenital, pharyngeal, and rectal swabs .

Purulent Gonococcal Monoarthritis (Septic Form) :

Presents as an acute, isolated, purulent monoarthritis (knee, wrist, or ankle) without classic tenosynovitis or cutaneous pustules. Synovial fluid culture is positive in approximately 50% of cases.

• Diagnostic Evaluation & Arthrocentesis Master Matrix
• Clinical Presentation

Acute Monoarticular Pain : Rapid onset (hours to days) of excruciating, constant pain, localized to a single large joint: Knee (>50% of cases) , hip (20%), shoulder (8%), ankle (7%), or wrist (6%).

The Hallmark Physical Exam Finding : Dramatic, painful restriction of BOTH ACTIVE AND PASSIVE RANGE OF MOTION . The patient maintains the joint in a position of maximum capsular volume (e.g., knee flexed at 30 to 45 degrees) and vigorously refuses even minor passive joint movement (e.g., "log-rolling" of the hip produces agony).

Local Signs : Large joint effusion, palpable warmth, erythema, and marked localized tenderness.

Systemic Signs : Low-grade or spiking fevers and tachycardia in 60% to 80% of patients. Caution : Up to 20% to 30% of elderly, uremic, cirrhotic, or immunosuppressed patients are completely afebrile and fail to demonstrate significant peripheral leukocytosis.

Important

THE MANDATORY ARTHROCENTESIS IMPERATIVE: Arthrocentesis (joint aspiration) must be performed IMMEDIATELY in every patient presenting with an acute, unexplained monoarticular joint effusion prior to the administration of systemic antibiotics .

Delaying aspiration or administering antibiotics before obtaining synovial fluid dramatically lowers culture sensitivity and impedes pathogen-directed antimicrobial therapy.

Synovial Fluid Analysis Master Table

Classification Clarity & Color Leukocyte Count (WBC/µL) Polymorphonuclear Leukocytes (% PMNs) Glucose Concentration Synovial / Clinical Conditions

Normal Transparent / Clear, Colorless <200 <25% Equal to blood glucose Normal physiological joint fluid

Class I: Non-Inflammatory Transparent, Clear to Straw-Yellow 200 to 2,000 <25% Equal to blood glucose Osteoarthritis, trauma, degenerative joint disease, osteochondritis dissecans

Class II: Inflammatory Translucent to Opaque, Cloudy Yellow 2,000 to 50,000 >50% Normal to mildly decreased Rheumatoid arthritis, Gout, Pseudogout (CPPD), Reactive arthritis, Psoriatic arthritis

Class III: Septic Opaque / Turbid / Purulent ("Frank Pus") >50,000 ; (Frequently >100,000 ) ≥75% to 90% Markedly decreased ; ( <50% of serum glucose ) Bacterial Septic Arthritis , Fungal/Mycobacterial arthritis (lower counts)

Class IV: Hemorrhagic Bloody / Opaque Red 200 to 2,000; (Numerous RBCs) <50% Equal to blood glucose Acute trauma, intra-articular fracture, ligamentous rupture (ACL tear), coagulopathy, hemophilia

Additional Synovial Fluid Parameters

Gram Stain : Positive in 50% to 70% of staphylococcal/streptococcal infections, but positive in only <25% of gonococcal infections. A negative Gram stain NEVER excludes septic arthritis.

Synovial Lactate : Elevated (>10 to 11 mmol/L) demonstrates >90% sensitivity for bacterial arthritis.

The "Crystals Do Not Rule Out Infection" Rule :

The identification of monosodium urate or calcium pyrophosphate crystals under polarized light DOES NOT rule out concurrent septic arthritis .

Septic arthritis and crystal-induced synovitis can coexist within the same joint ("coexistent septic and crystal arthritis"). If synovial fluid shows >50,000 WBCs/µL or if clinical suspicion for infection is high, full empiric antimicrobial therapy must be continued pending final 48-hour bacterial cultures.

Emergency Therapeutic Management of Septic Arthritis SEPTIC ARTHRITIS MANAGEMENT PROTOCOL

• ┌────────────────────────────────────────────────────────────────────────┐
• │ STEP 1: IMMEDIATE DIAGNOSTIC ARTHROCENTESIS │
• │ • Send fluid for: Cell count + diff, Gram stain, Aerobic/Anaerobic │
• │ cultures, Polarized microscopy (crystals), Glucose, Lactate │
• │ • Obtain 2 sets of peripheral blood cultures │
• └───────────────────────────────────┬────────────────────────────────────┘
• │
• ▼
• ┌────────────────────────────────────────────────────────────────────────┐
• │ STEP 2: IMMEDIATE EMPIRIC INTRAVENOUS ANTIMICROBIALS │
• │ • Initiate immediately AFTER joint fluid aspiration is completed │
• │ • IV Vancomycin 15-20 mg/kg q8-12h (MRSA & Gram-positives) │
• │ PLUS │
• │ • IV Ceftriaxone 1-2 g daily (N. gonorrhoeae & Gram-negatives) │
• │ • If IVDU / Pseudomonas risk: Substitute Ceftriaxone with Cefepime 2g │
• └───────────────────────────────────┬────────────────────────────────────┘
• │
• ▼
• ┌────────────────────────────────────────────────────────────────────────┐
• │ STEP 3: URGENT ORTHOPEDIC JOINT DECOMPRESSION │
• │ • Emergent orthopedic surgical consultation │
• │ • Modalities: Arthroscopic debridement & lavage (knee/shoulder) OR │
• │ Open arthrotomy (hip, difficult joints) OR Serial daily needle aspir │
• │ • Antibiotics alone CANNOT sterilize an infected, pressurized joint │
• └────────────────────────────────────────────────────────────────────────┘
• 1. Empiric Intravenous Antimicrobial Therapy

Empiric antimicrobial therapy must be initiated intravenously immediately following diagnostic arthrocentesis:

Standard Empiric Combination :

Vancomycin 15 to 20 mg/kg IV every 8 to 12 hours (targets MRSA, MSSA, and penicillin-resistant Streptococcus species);

PLUS Ceftriaxone 1 g to 2 g IV daily (targets Neisseria gonorrhoeae and community-acquired Gram-negative bacilli).

High Risk for Pseudomonas aeruginosa / Nosocomial Gram-Negatives (Injection drug use, institutionalized patients, indwelling urinary catheter):

Substitute Ceftriaxone with an antipseudomonal beta-lactam: Cefepime 2 g IV every 8 hours OR Piperacillin-tazobactam 4.5 g IV every 6 hours .

Pathogen-Directed De-escalation (Once cultures and susceptibilities return):

Methicillin-Susceptible S. aureus (MSSA) : De-escalate to Cefazolin 2 g IV every 8 hours or Nafcillin 2 g IV every 4 hours (superior bactericidal clearance compared to vancomycin).

Neisseria gonorrhoeae : Ceftriaxone 1 g to 2 g IV daily for 7 to 14 days.

Streptococcus pneumoniae / pyogenes : Penicillin G 2 to 4 million units IV every 4 hours or Ceftriaxone 2 g IV daily .

Duration : Typically 3 to 4 weeks of targeted antibiotic therapy (minimum 2 weeks IV, followed by bioavailable oral therapy based on clinical resolution and normalizing inflammatory markers [ESR/CRP]).

2. Urgent Joint Decompression: Orthopedic Modalities

Systemic antimicrobials cannot penetrate an infected joint space with elevated hydrostatic pressure to sterilize purulent exudate. Evacuation of purulent fluid is mandatory:

Arthroscopic Debridement & Lavage : Treatment of choice for the knee, shoulder, and ankle; allows direct visualization, lysis of fibrinous loculations, thorough debridement of inflamed necrotic synovium, and copious high-volume irrigation.

Open Arthrotomy : Required for hip septic arthritis (due to deep anatomical location and high risk of avascular necrosis of the femoral head), joints with extensive osteomyelitis or hardware, or cases where arthroscopy fails to clear infection.

Serial Closed-Needle Aspiration : Reserved for easily accessible superficial joints (e.g., knee) in patients responding rapidly to medical therapy or poor surgical candidates unfit for general anesthesia; performed daily until effusions cease to reaccumulate and synovial fluid cultures become sterile.

Acute Microcrystalline Crises: Gout versus CPPD (Pseudogout)

Crystal arthropathies represent acute, excruciating, inflammatory mono- or oligo-arthritides caused by the intra-articular precipitation of microcrystals that trigger the innate immune system. POLARIZED LIGHT MICROSCOPY CRYSTAL PHYSICS

• MONOSODIUM URATE (GOUT) CALCIUM PYROPHOSPHATE (CPPD)
• ┌─────────────────────────────────┐ ┌─────────────────────────────────┐
• │ • Shape: Needle-shaped, sharp │ │ • Shape: Rhomboid / Parallelepip│
• │ • Birefringence: STRONGLY NEG │ │ • Birefringence: WEAKLY POS │
• │ • PARALLEL to axis: BRIGHT YELLOW│ │ • PARALLEL to axis: BLUE │
• │ • PERPENDICULAR: BLUE │ │ • PERPENDICULAR: YELLOW │
• └─────────────────────────────────┘ └─────────────────────────────────┘
• 1. Gout (Monosodium Urate Crystal Deposition)

Pathogenesis :

Chronic hyperuricemia (serum urate >6.8 mg/dL, the physiological solubility limit at 37°C) leads to the nucleation and precipitation of monosodium urate (MSU) monohydrate crystals in synovial fluid, synovial membranes, and periarticular tissues.

Phagocytosis of MSU crystals by intra-articular macrophages triggers the NLRP3 inflammasome complex .

Activated NLRP3 activates caspase-1, which cleaves pro-interleukin-1β into active interleukin-1β (IL-1β) .

Massive IL-1β secretion activates vascular endothelial cells, triggering intense chemotactic recruitment of polymorphonuclear neutrophils into the joint space, resulting in severe acute synovitis.

Clinical Presentation :

Explosive, agonizing pain that characteristically peaks in intensity within 12 to 24 hours of onset, often awakening the patient from sleep in the early morning hours.

Podagra (1st Metatarsophalangeal Joint) : Involved in >50% of initial attacks and >80% of patients over their lifetime. Other frequent sites: midfoot (instep), ankle, knee, and olecranon bursa.

Marked localized erythema, swelling, warmth, and exquisite hypersensitivity (the touch of a bedsheet or gentle airflow elicits unbearable pain). Periarticular erythema frequently mimics cellulitis.

Polarized Light Microscopy :

Demonstrates needle-shaped, intensely negatively birefringent crystals .

Optical Physics Under Red Compensator : When the long axis of the needle-shaped crystal is oriented parallel to the slow axis of the red compensator filter, the crystal appears bright yellow . When rotated perpendicular to the compensator axis, the crystal appears blue .

Serum Urate Levels During an Acute Flare :

Critical Board Exam Fact : Serum urate concentrations are completely normal in up to 30% to 40% of patients during an acute gout attack. High circulating levels of systemic cortisol and IL-6 during acute inflammation induce renal uricosuria, lowering serum urate. A normal serum uric acid level NEVER excludes acute gout; definitive diagnosis requires polarizing microscopy of synovial fluid.

Evidence-Based Acute Gout Flare Management

Pharmacologic therapy must be initiated as early as possible (ideally within 24 hours of symptom onset). Three first-line anti-inflammatory classes demonstrate equal efficacy; selection depends upon patient comorbidities:

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) :

Regimen : Full anti-inflammatory doses: Indomethacin 50 mg PO TID or Naproxen 500 mg PO BID for 5 to 7 days, tapering rapidly after symptom resolution.

Contraindications : Chronic kidney disease (eGFR <60 mL/min), active peptic ulcer disease, severe heart failure, cirrhosis, and concurrent therapeutic anticoagulation.

Colchicine :

Mechanism : Inhibits microtubule polymerization by binding tubulin, blocking neutrophil chemotaxis, adhesion, and inflammasome activation.

Low-Dose FDA Dosing Protocol : 1.2 mg PO at the first sign of flare, followed by 0.6 mg PO 1 hour later (total dose: 1.8 mg over 1 hour). After 12 hours, continue 0.6 mg PO once or twice daily until the flare resolves.

Efficacy Window : Must be initiated within 36 hours of flare onset to provide clinical benefit.

Toxicity & Drug Interactions : High doses cause severe diarrhea, vomiting, and abdominal cramping. Dose must be reduced in moderate-to-severe renal impairment. Strictly contraindicated in patients receiving strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or P-glycoprotein inhibitors (e.g., cyclosporine) due to risks of fatal colchicine neuromyopathy and bone marrow suppression.

Corticosteroids :

First-line choice in patients with renal insufficiency, heart failure, or gastrointestinal ulcer disease where NSAIDs and colchicine are contraindicated.

Oral Regimen : Prednisone 30 to 40 mg PO daily for 5 days, or tapered over 7 to 10 days.

Intra-Articular Injection : Triamcinolone acetonide (10 to 40 mg) injected directly into the joint space is highly effective for isolated monoarticular flares (e.g., knee) once joint infection has been definitively excluded via prior fluid analysis.

Critical Board Exam Rules Governing Urate-Lowering Therapy (ULT)

Caution

THE CARDINAL RULES OF ALLOPURINOL MANAGEMENT DURING A FLARE:

DO NOT INITIATE OR TITRATE URATE-LOWERING THERAPY DURING AN ACUTE GOUT FLARE. Rapid shifts in serum urate concentrations alter crystal surface solubility dynamics, promoting crystal fracturing and shedding into the synovial space, which paradoxically prolongs and severely intensifies the acute inflammatory attack. Wait at least 2 to 4 weeks after complete clinical resolution of the flare before starting allopurinol or febuxostat, and always co-prescribe anti-inflammatory flare prophylaxis (e.g., low-dose colchicine 0.6 mg daily or naproxen 250 mg BID) for 3 to 6 months.

DO NOT STOP CHRONIC ALLOPURINOL IF THE PATIENT IS ALREADY TAKING IT. If a patient experiences a breakthrough acute flare while taking chronic allopurinol, continue the baseline allopurinol dose without interruption . Abruptly discontinuing allopurinol triggers a sharp rebound surge in serum urate, precipitating further crystal instability and markedly prolonging the flare. Treat the acute flare vigorously with NSAIDs, colchicine, or steroids while maintaining chronic allopurinol unchanged.

Loading diagram... Emergency Diagnostic & Management Pathway for Acute Monoarthritis